Analysts Set Expectations for LFCR Q4 Earnings

Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Research analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for shares of Lifecore Biomedical in a note issued to investors on Wednesday, May 21st. William Blair analyst M. Smock anticipates that the company will earn $0.04 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.91) per share. William Blair also issued estimates for Lifecore Biomedical’s Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.32) EPS and FY2028 earnings at ($0.20) EPS.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. The firm had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.23 million.

Lifecore Biomedical Stock Performance

NASDAQ:LFCR opened at $6.72 on Friday. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The firm has a market capitalization of $248.81 million, a price-to-earnings ratio of -12.00 and a beta of 0.65. The company’s 50-day moving average is $6.49 and its two-hundred day moving average is $6.56. Lifecore Biomedical has a 1-year low of $3.68 and a 1-year high of $7.99.

Institutional Trading of Lifecore Biomedical

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC lifted its position in Lifecore Biomedical by 301.7% in the third quarter. Barclays PLC now owns 29,944 shares of the company’s stock valued at $147,000 after buying an additional 22,489 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in shares of Lifecore Biomedical by 61.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 27,184 shares of the company’s stock valued at $202,000 after acquiring an additional 10,320 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Lifecore Biomedical by 71.9% in the 4th quarter. Bank of New York Mellon Corp now owns 80,572 shares of the company’s stock valued at $599,000 after acquiring an additional 33,690 shares during the period. Rhumbline Advisers lifted its holdings in shares of Lifecore Biomedical by 125.9% in the 4th quarter. Rhumbline Advisers now owns 55,723 shares of the company’s stock worth $414,000 after acquiring an additional 31,056 shares during the last quarter. Finally, Rangeley Capital LLC purchased a new position in shares of Lifecore Biomedical during the 4th quarter worth approximately $325,000. 83.36% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Lifecore Biomedical

In other news, major shareholder Aron R. English sold 15,847 shares of the company’s stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $7.01, for a total value of $111,087.47. Following the transaction, the insider now owns 1,714,070 shares of the company’s stock, valued at $12,015,630.70. This represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 99,122 shares of company stock worth $697,347 in the last 90 days. Insiders own 32.20% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.